Oppenheimer Thinks Urogen Pharma Ltd’s Stock is Going to Recover

By Carrie Williams

Oppenheimer analyst Leland Gershell maintained a Buy rating on Urogen Pharma Ltd (URGNResearch Report) today. The company’s shares opened today at $38.13, close to its 52-week low of $34.61.

According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.0% and a 43.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Anchiano Therapeutics Ltd, Avenue Therapeutics Inc, and Evofem Biosciences Inc.

Currently, the analyst consensus on Urogen Pharma Ltd is a Strong Buy with an average price target of $65, a 70.5% upside from current levels. In a report issued on March 5, Stifel Nicolaus also reiterated a Buy rating on the stock with a $63 price target.

See today’s analyst top recommended stocks >>

Based on Urogen Pharma Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $23.72 million. In comparison, last year the company had a GAAP net loss of $10.07 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.